FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.

Shares of FreightCar America Inc (NASDAQ:RAIL) fell sharply in pre-market trading after the company reported worse-than-expected quarterly financial results.

FreightCar America reported quarterly earnings of 16 cents per share which missed the analyst consensus estimate of 19 cents per share. The company reported quarterly sales of $125.567 million which missed the analyst consensus estimate of $144.768 million.

FreightCar America shares dipped 20.4% to $10.10 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Garden Stage Ltd (NASDAQ:GSIW) shares dipped 36% to $21.25 in pre-market trading after jumping 248% on Monday.
• BioNTech SE – ADR (NASDAQ:BNTX) dipped 16.5% to $85.29 in pre-market trading following fourth-quarter results.
• Evotec SE (NASDAQ:EVO) tumbled 15.7% to $2.55 in pre-market trading.
• Yalla Group Ltd – ADR (NYSE:YALA) fell 8.1% to $6.54 in pre-market trading after the company reported fourth-quarter results and announced a new $150 million share repurchase program.
• Crispr Therapeutics AG (NASDAQ:CRSP) declined 7.1% to $54.60 in pre-market trading. CRISPR Therapeutics announced a proposed convertible senior notes offering.
• PROG Holdings Inc (NYSE:PRG) fell 7.1% to $30.41 in pre-market trading after the company lowered its FY2026 sales guidance.
• Battalion Oil Corp (NYSE:BATL) declined 5.6% to $17.69 in pre-market trading after dipping 16% on Monday.
• Kingsoft Cloud Holdings Ltd (NASDAQ:KC) fell 5.6% to $13.48 in pre-market trading after jumping 19% on Monday.
• Relmada Therapeutics Inc (NASDAQ:RLMD) declined 5.4% to $6.78 in pre-market trading. Relmada Therapeutics shares jumped 61% on Monday after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer.
• Kohls Corp (NYSE:KSS) fell 3.8% to $14.23 in pre-market trading following fourth-quarter results.

Photo via Shutterstock